

Urgent Field Safety Notice

10818631, Rev. B June 2014

ADVIA Centaur[®] ADVIA Centaur[®] XP ADVIA Centaur[®] CP

Troponin Ultra ReadyPack Variability

Our records indicate that your facility has received the following product:

Table 1. ADVIA Centaur Affected Product

Assay	Catalog Number	Siemens Material Number (SMN)	Kit Lots Ending In	Expiration
TNI-Ultra	02789602 (100 tests)	10317708 (100 tests)	078	18 July, 2014
			079	18 July, 2014
	02790309 (500 tests)	10317709 (500 tests)	082	27 September, 2014
			083	29 November, 2014
			084	28 December, 2014

Reason for Correction

Siemens Healthcare Diagnostics, through internal investigation of lot 084, has confirmed that the solid phase reagent in some of the ADVIA Centaur[®] TNI-Ultra ReadyPacks[®], lot 084, is darker in appearance, creating a potential for incorrect control and patient results.

As a precaution, this correction applies to all in-date lots listed in Table 1. Product may continue to be used following the instructions below.

This issue impacts the ADVIA Centaur/ADVIA Centaur XP and ADVIA Centaur CP platforms.

Risk to Health

Siemens estimates that 0.2% of ReadyPacks may be affected. The bias encountered in these ReadyPacks in most circumstances would be very pronounced with low level controls. There are three possibilities for impaired performance with the affected ReadyPack:

- If calibration and sample testing is performed with the same affected ReadyPack, increased imprecision may affect serial testing near the 99th percentile. A delay in detection of ischemia is possible if the serial testing of slightly elevated results is not confirmed due to the imprecision.
- If the instrument is calibrated on a non-affected ReadyPack and then there is a switch over to an affected ReadyPack, there is a risk of positive bias. The effect of this bias would be pronounced in QC near the 99th percentile and would be obvious. Assuming QC did not catch the shift, there is potential to have patients below but near the 99th percentile to test slightly above the 99th percentile.

If the instrument is calibrated on an affected ReadyPack and then there is a switch over
to a non-affected ReadyPack, there is potential for negative bias. This bias would be
very pronounced in low or midrange controls. The bias could potentially result in a
patient or QC value of less than 0.3 ng/mL (μg/L) to test below the 99th percentile.
Assuming QC is not run at ReadyPack changes but rather at shift changes, the QC shift
would be pronounced enough to result in a review of patients on the previous shift.

If QC has demonstrated a shift, a look back for patient results generated with that ReadyPack should be considered. Following the instructions below, calibration on each ReadyPack is required. Please follow Instructions For Use (IFU) guidelines for sample storage and stability.

Actions to be Taken by the Customer

- Do not place more than one TNI-Ultra ReadyPack on the system at a time.
- With each ReadyPack placed on the system, calibrate the ReadyPack and run controls to ensure accurate control and patient values.
- Patient TnI-Ultra results produced with this assay are acceptable if they follow acceptable calibration with valid quality control results.
- Upon receipt of kit lots ending in 086 and higher, calibration of each ReadyPack is NOT required; please refer to the assay IFU for calibration interval.
- Please review this letter with your Medical Director.
- Complete and return the Field Correction Effectiveness Check attached to this letter within 30 days.

Please retain this letter with your laboratory records, and forward this letter to those who may have received this product.

We apologize for the inconvenience this situation has caused. If you have any questions, please contact your Siemens Customer Care Center or your local Siemens technical support representative.

Siemens Healthcare Diagnostics 511 Benedict Ave. Tarrytown, NY 10591 www.siemens.com/diagnostics

ADVIA Centaur and ReadyPack are trademarks of Siemens Healthcare Diagnostics.

FIELD CORRECTION EFFECTIVENESS CHECK

Troponin Ultra ReadyPack Variability

This response form is to confirm receipt of the enclosed Siemens Healthcare Diagnostics Urgent Field Safety Notice 10818631, Rev. B dated June 2014 regarding Troponin Ultra ReadyPack Variability. Please read the question and indicate the appropriate answer. Fax this completed form to Siemens Healthcare Diagnostics at the fax number provided at the bottom of this page.

I have read and understood the Urgent Fie instructions provided in this letter.	eld Safety Notice	Yes	No 🗆
Name of person completing questionnaire:			
_Title:			
Institution:	Instrument Seri	ment Serial Number:	
Street:			
City:	State:		
Phone:	Country:		

Please fax this completed form to the Customer Care Center at (###) ###-####. If you have any questions, contact your local Siemens technical support representative.